세계의 조직 플라스미노겐 활성화 인자 시장 보고서(2025년)

Tissue Plasminogen Activator Global Market Report 2025

US $ 4,490 ￦ 6,253,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,039,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,824,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

조직 플라스미노겐 활성화 인자(tissue plasminogen activator) 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 9.0%의 연평균 복합 성장률(CAGR)로 53억 2,000만 달러에 달할 것으로 예측됩니다. 혈전증 위험이 높은 고령화, 빠른 혈전 용해제에 대한 수요 증가, 신흥국의 의료비 지출 증가, 폐색전증 유병률 증가, 새로운 치료 적응증을 찾기 위한 임상시험의 진행 등이 예측 기간 동안 성장을 견인할 것으로 보입니다. 주요 동향으로는 카테터 지시 혈전 용해 요법으로의 전환, 뇌졸중 분류에 인공지능의 통합, tPA 바이오시밀러의 등장, ARDS 및 코로나19 합병증에 대한 tPA 사용에 대한 연구 증가, 정밀 투약 기술 채택 등이 있습니다.

생활습관병의 유병률 증가는 조직 플라스미노겐 활성화 인자 시장의 성장을 가속할 것으로 예측됩니다. 주로 비감염성 질환인 이들 질환은 영양 부족, 운동 부족, 흡연, 과도한 음주와 같은 건강에 해로운 생활 습관에 기인하여 심혈관 질환, 당뇨병, 고혈압과 같은 증상을 유발합니다. 이러한 생활습관병의 급증은 식생활의 변화와 신체활동의 감소에 기인한 바가 크며, 앉아서 생활하는 습관은 신진대사의 건강을 해치고 혈전성 사건의 유발에 중요한 역할을 합니다. 조직 플라스미노겐 활성화 인자(tPA)는 허혈성 뇌졸중 및 심근경색과 관련된 위험한 혈전을 용해시킴으로써 이러한 장애의 결과에 대처하여 사망률을 낮추고 환자의 예후를 개선할 수 있습니다. 예를 들어, 영국 정부 기관인 Office for Health Improvement and Disparities의 데이터에 따르면, 2022년부터 2023년까지 영국 성인의 약 64.0%가 과체중 또는 비만이며, 이는 전년도 63.8%에서 증가한 것으로 나타났습니다. 밝혀졌습니다. 비만만 해도 성인의 26.2%가 앓고 있으며, 비만율은 남녀 간 비슷한 수준이었으나, 여성(58.6%)에 비해 남성(69.2%)의 과체중 유병률이 더 높았습니다. 이러한 생활습관병 증가가 조직 플라스미노겐 활성화 인자 수요를 견인하는 중요한 요인이 되고 있습니다.

조직 플라스미노겐 활성화 인자 시장의 주요 기업들은 뇌졸중 급성기 치료를 개선하기 위해 단회 혈전 용해제와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 이러한 속효성 약물은 심근경색, 뇌경색, 폐색전증 등의 증상에서 혈전을 신속하게 파괴하고 정상적인 혈류를 회복시키기 위해 1회 정맥 투여로 투여됩니다. 예를 들어, 2025년 3월 미국 생명공학 기업 제네텍은 성인 급성 허혈성 뇌졸중(AIS) 치료제로 TNKase(Tenecteplase)를 미국 식품의약국(FDA)의 승인을 받았습니다. 이번 승인은 젠젠텍의 두 번째 뇌졸중 치료제로, TNKase는 액티바제(알테플라제)에 비해 60분간의 정맥주입이 아닌 5초간의 정맥주입으로 보다 효율적이고 간편한 치료방법을 제공합니다. 이번 승인은 TNKase가 Activase와 마찬가지로 AIS 환자에게 안전하고 효과적이라는 AcT 임상시험에서 얻은 확실한 임상적 근거를 바탕으로 이루어졌습니다. 이 혁신은 급성 허혈성 뇌졸중 환자의 장기적인 장애와 사망률을 감소시키는데 매우 중요한 치료의 신속성과 용이성을 개선할 것으로 기대됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 조직 플라스미노겐 활성화 인자 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 조직 플라스미노겐 활성화 인자 시장 : 성장률 분석
• 세계의 조직 플라스미노겐 활성화 인자 시장 실적 : 규모와 성장, 2019-2024
• 세계의 조직 플라스미노겐 활성화 인자 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 조직 플라스미노겐 활성화 인자 전체 시장(TAM)

제6장 시장 세분화

• 세계의 조직 플라스미노겐 활성화 인자 시장 : 제품 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Alteplase
• Tenecteplase
• Reteplase
• 기타 제품 유형
• 세계의 조직 플라스미노겐 활성화 인자 시장 : 제형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 주사용 분말
• 주사액
• 세계의 조직 플라스미노겐 활성화 인자 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 직접 판매
• 유통업체
• 온라인 약국
• 소매 약국
• 세계의 조직 플라스미노겐 활성화 인자 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 허혈성 뇌졸중
• 심근경색
• 폐색전증
• 혈전용해 요법
• 기타 용도
• 세계의 조직 플라스미노겐 활성화 인자 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 전문 심장 클리닉
• 응급 의료 서비스(EMS)
• 외래수술센터(ASC)
• 세계의 조직 플라스미노겐 활성화 인자 시장 : Alteplase 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Recombinant Alteplase
• Biosimilar Alteplase
• Lyophilized Alteplase
• 세계의 조직 플라스미노겐 활성화 인자 시장 : Tenecteplase 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Recombinant Tenecteplase
• Genetically Engineered Tenecteplase
• Long-Acting Tenecteplase
• 세계의 조직 플라스미노겐 활성화 인자 시장 : Reteplase 세분화(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Recombinant Reteplase
• Double-Chain Reteplase
• Single-Bolus Reteplase
• 세계의 조직 플라스미노겐 활성화 인자 시장, 기타 제품 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Monteplase
• Lanoteplase
• Desmoteplase
• Combination Agents With tPA Analogs

제7장 지역별/국가별 분석

• 세계의 조직 플라스미노겐 활성화 인자 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 조직 플라스미노겐 활성화 인자 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 조직 플라스미노겐 활성화 인자 시장 : 경쟁 구도
• 조직 플라스미노겐 활성화 인자 시장 : 기업 개요
  • F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Boehringer Ingelheim International GmbH : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Genentech Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• CHIESI Farmaceutici S.p.A.
• Cadila Pharmaceuticals Ltd.
• Lupin Ltd.
• Sigma-Aldrich
• Gennova Biopharmaceuticals Ltd.
• Angde Biological Pharmaceutical Co. Ltd.
• Reliance Life Sciences
• Cedarlane Laboratories
• Microbix Biosystems
• Taj Pharmaceuticals
• BPS Bioscience
• Aviva Systems Biology
• Biotang Inc.
• Reprokine
• Molecular Depot

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 조직 플라스미노겐 활성화 인자 시장(2029년) : 새로운 기회를 제공하는 국가
• 조직 플라스미노겐 활성화 인자 시장(2029년) : 새로운 기회를 제공하는 부문
• 조직 플라스미노겐 활성화 인자 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Tissue plasminogen activator (tPA) is a serine protease enzyme primarily produced by endothelial cells that catalyzes the conversion of plasminogen into plasmin, the primary enzyme responsible for clot breakdown. It is commonly used as a thrombolytic agent in clinical settings for the treatment of acute ischemic stroke, pulmonary embolism, and myocardial infarction, helping to dissolve blood clots and restore normal blood flow.

The main product types of tissue plasminogen activator include alteplase, tenecteplase, reteplase, and others. Alteplase is a recombinant form of tPA that serves as a thrombolytic agent to dissolve blood clots in conditions such as acute ischemic stroke, myocardial infarction, and pulmonary embolism. These products are available in dosage forms such as powder for injection and solution for injection. They are distributed through various channels, including direct sales, distributors, online pharmacies, and retail pharmacies. These tPA products are used in applications such as thrombolysis for ischemic stroke, myocardial infarction, and pulmonary embolism, serving end users such as hospitals, specialized cardiac clinics, emergency medical services (EMS), and ambulatory surgical centers.

The tissue plasminogen activator market research report is one of a series of new reports from The Business Research Company that provides tissue plasminogen activator market statistics, including tissue plasminogen activator industry global market size, regional shares, competitors with a tissue plasminogen activator market share, detailed tissue plasminogen activator market segments, market trends and opportunities, and any further data you may need to thrive in the tissue plasminogen activator industry. This tissue plasminogen activator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tissue plasminogen activator market size has grown strongly in recent years. It will grow from $3.45 billion in 2024 to $3.77 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the rising prevalence of ischemic stroke, an increasing incidence of myocardial infarction, growing awareness of thrombolytic therapy, improvements in emergency care infrastructure, and government initiatives aimed at reducing cardiovascular mortality.

The tissue plasminogen activator market size is expected to see strong growth in the next few years. It will grow to $5.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period is expected to be driven by an aging population at higher risk of thrombosis, increasing demand for faster-acting thrombolytic agents, growing healthcare spending in emerging economies, a rising prevalence of pulmonary embolism, and ongoing clinical trials exploring new therapeutic indications. Key trends anticipated include a shift toward catheter-directed thrombolysis, the integration of artificial intelligence in stroke triage, the emergence of biosimilars for tPA, increasing research into tPA's use in ARDS and COVID-19 complications, and the adoption of precision dosing technologies.

The increasing prevalence of lifestyle-related disorders is anticipated to drive the growth of the tissue plasminogen activator market. These disorders, which are primarily non-communicable, stem from unhealthy lifestyle habits such as poor nutrition, lack of exercise, smoking, and excessive alcohol consumption, leading to conditions such as cardiovascular disease, diabetes, and hypertension. This surge in lifestyle-related disorders is largely due to shifting dietary patterns and decreased physical activity, with sedentary lifestyles playing a significant role in disrupting metabolic health and triggering thrombotic events. Tissue plasminogen activator (tPA) addresses the consequences of these disorders by dissolving dangerous blood clots, which are often associated with ischemic strokes and myocardial infarctions, thereby reducing mortality and improving outcomes for patients. For example, data from the Office for Health Improvement and Disparities, a UK government body, revealed that in 2022-2023, approximately 64.0% of adults in England were either overweight or obese, up from 63.8% in the previous year. Obesity alone affected 26.2% of adults, with men having a higher prevalence of being overweight (69.2%) compared to women (58.6%), though obesity rates were similar between the genders. This increase in lifestyle-related conditions is a key factor driving the demand for tissue plasminogen activator.

Major players in the tissue plasminogen activator market are focusing on developing innovative treatments, such as single-bolus thrombolytic agents, to improve acute stroke therapy. These fast-acting drugs are given in a single intravenous dose to quickly break down blood clots and restore normal blood flow in conditions such as myocardial infarction, stroke, or pulmonary embolism. For instance, in March 2025, Genentech Inc., a U.S.-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for TNKase (tenecteplase) as a treatment for acute ischemic stroke (AIS) in adults. This approval marks Genentech's second stroke management drug, with TNKase offering a more efficient and simpler treatment method compared to Activase (alteplase), requiring just a five-second intravenous bolus rather than a 60-minute infusion. The approval is based on robust clinical evidence from the AcT trial, which showed that TNKase is as safe and effective as Activase for AIS patients. This innovation is expected to improve the speed and ease of treatment, which is critical in reducing long-term disability and mortality in patients experiencing acute ischemic strokes.

In January 2023, Shalamar Institute of Health Sciences (SIHS), a medical complex based in Pakistan, signed a Memorandum of Understanding (MoU) with Services Institute of Medical Sciences (SIMS) to enhance collaboration between healthcare institutions in advancing stroke care. The agreement aims to establish a cooperative framework for improving patient outcomes through the coordinated use of tissue plasminogen activator (tPA) in stroke treatment. It includes the development of standardized thrombolytic protocols, joint clinical training programs, and efforts to align stroke management practices with global best practices and the institutions' capabilities. Services Institute of Medical Sciences (SIMS) is a public medical college in Pakistan.

Major players in the tissue plasminogen activator market are F. Hoffmann-La Roche Ltd., Bayer AG, Abbott Laboratories, Boehringer Ingelheim International GmbH, Genentech Inc., CHIESI Farmaceutici S.p.A., Cadila Pharmaceuticals Ltd., Lupin Ltd., Sigma-Aldrich, Gennova Biopharmaceuticals Ltd., Angde Biological Pharmaceutical Co. Ltd., Reliance Life Sciences, Cedarlane Laboratories, Microbix Biosystems, Taj Pharmaceuticals, BPS Bioscience, Aviva Systems Biology, Biotang Inc., Reprokine, and Molecular Depot.

North America was the largest region in the tissue plasminogen activator market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tissue plasminogen activator report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tissue plasminogen activator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tissue plasminogen activator market consists of sales of biosimilar formulations, recombinant tissue plasminogen activator (rtPA) variants, single-dose prefilled syringes, dual-chamber injection systems, and lyophilized tPA kits with diluent. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tissue Plasminogen Activator Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tissue plasminogen activator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tissue plasminogen activator ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tissue plasminogen activator market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Alteplase; Tenecteplase; Reteplase; Other Product Types
• 2) By Dosage Form: Powder For Injection; Solution For Injection
• 3) By Distribution Channel: Direct Sales; Distributors; Online Pharmacies; Retail Pharmacies
• 4) By Application: Ischemic Stroke; Myocardial Infarction; Pulmonary Embolism; Thrombolysis; Other Applications
• 5) By End-User: Hospitals; Specialized Cardiac Clinics; Emergency Medical Services (EMS); Ambulatory Surgical Centers
• Subsegments:
• 1) By Alteplase: Recombinant Alteplase; Biosimilar Alteplase; Lyophilized Alteplase
• 2) By Tenecteplase: Recombinant Tenecteplase: Genetically Engineered Tenecteplase; Long-Acting Tenecteplase
• 3) By Reteplase: Recombinant Reteplase; Double-Chain Reteplase; Single-Bolus Reteplase
• 4) By Other Product Types: Monteplase; Lanoteplase; Desmoteplase; Combination Agents With tPA Analogs
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bayer AG; Abbott Laboratories; Boehringer Ingelheim International GmbH; Genentech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tissue Plasminogen Activator Market Characteristics

3. Tissue Plasminogen Activator Market Trends And Strategies

4. Tissue Plasminogen Activator Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tissue Plasminogen Activator Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tissue Plasminogen Activator PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tissue Plasminogen Activator Market Growth Rate Analysis
• 5.4. Global Tissue Plasminogen Activator Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tissue Plasminogen Activator Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tissue Plasminogen Activator Total Addressable Market (TAM)

6. Tissue Plasminogen Activator Market Segmentation

• 6.1. Global Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alteplase
• Tenecteplase
• Reteplase
• Other Product Types
• 6.2. Global Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Powder For Injection
• Solution For Injection
• 6.3. Global Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Distributors
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Tissue Plasminogen Activator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ischemic Stroke
• Myocardial Infarction
• Pulmonary Embolism
• Thrombolysis
• Others Applications
• 6.5. Global Tissue Plasminogen Activator Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialized Cardiac Clinics
• Emergency Medical Services (EMS)
• Ambulatory Surgical Centers
• 6.6. Global Tissue Plasminogen Activator Market, Sub-Segmentation Of Alteplase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Alteplase
• Biosimilar Alteplase
• Lyophilized Alteplase
• 6.7. Global Tissue Plasminogen Activator Market, Sub-Segmentation Of Tenecteplase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Tenecteplase
• Genetically Engineered Tenecteplase
• Long-Acting Tenecteplase
• 6.8. Global Tissue Plasminogen Activator Market, Sub-Segmentation Of Reteplase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Reteplase
• Double-Chain Reteplase
• Single-Bolus Reteplase
• 6.9. Global Tissue Plasminogen Activator Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monteplase
• Lanoteplase
• Desmoteplase
• Combination Agents With tPA Analogs

7. Tissue Plasminogen Activator Market Regional And Country Analysis

• 7.1. Global Tissue Plasminogen Activator Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tissue Plasminogen Activator Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tissue Plasminogen Activator Market

• 8.1. Asia-Pacific Tissue Plasminogen Activator Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tissue Plasminogen Activator Market

• 9.1. China Tissue Plasminogen Activator Market Overview
• 9.2. China Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tissue Plasminogen Activator Market

• 10.1. India Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tissue Plasminogen Activator Market

• 11.1. Japan Tissue Plasminogen Activator Market Overview
• 11.2. Japan Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tissue Plasminogen Activator Market

• 12.1. Australia Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tissue Plasminogen Activator Market

• 13.1. Indonesia Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tissue Plasminogen Activator Market

• 14.1. South Korea Tissue Plasminogen Activator Market Overview
• 14.2. South Korea Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tissue Plasminogen Activator Market

• 15.1. Western Europe Tissue Plasminogen Activator Market Overview
• 15.2. Western Europe Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tissue Plasminogen Activator Market

• 16.1. UK Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tissue Plasminogen Activator Market

• 17.1. Germany Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tissue Plasminogen Activator Market

• 18.1. France Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tissue Plasminogen Activator Market

• 19.1. Italy Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tissue Plasminogen Activator Market

• 20.1. Spain Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tissue Plasminogen Activator Market

• 21.1. Eastern Europe Tissue Plasminogen Activator Market Overview
• 21.2. Eastern Europe Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tissue Plasminogen Activator Market

• 22.1. Russia Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tissue Plasminogen Activator Market

• 23.1. North America Tissue Plasminogen Activator Market Overview
• 23.2. North America Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tissue Plasminogen Activator Market

• 24.1. USA Tissue Plasminogen Activator Market Overview
• 24.2. USA Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tissue Plasminogen Activator Market

• 25.1. Canada Tissue Plasminogen Activator Market Overview
• 25.2. Canada Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tissue Plasminogen Activator Market

• 26.1. South America Tissue Plasminogen Activator Market Overview
• 26.2. South America Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tissue Plasminogen Activator Market

• 27.1. Brazil Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tissue Plasminogen Activator Market

• 28.1. Middle East Tissue Plasminogen Activator Market Overview
• 28.2. Middle East Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tissue Plasminogen Activator Market

• 29.1. Africa Tissue Plasminogen Activator Market Overview
• 29.2. Africa Tissue Plasminogen Activator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tissue Plasminogen Activator Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tissue Plasminogen Activator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tissue Plasminogen Activator Market Competitive Landscape And Company Profiles

• 30.1. Tissue Plasminogen Activator Market Competitive Landscape
• 30.2. Tissue Plasminogen Activator Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Tissue Plasminogen Activator Market Other Major And Innovative Companies

• 31.1. CHIESI Farmaceutici S.p.A.
• 31.2. Cadila Pharmaceuticals Ltd.
• 31.3. Lupin Ltd.
• 31.4. Sigma-Aldrich
• 31.5. Gennova Biopharmaceuticals Ltd.
• 31.6. Angde Biological Pharmaceutical Co. Ltd.
• 31.7. Reliance Life Sciences
• 31.8. Cedarlane Laboratories
• 31.9. Microbix Biosystems
• 31.10. Taj Pharmaceuticals
• 31.11. BPS Bioscience
• 31.12. Aviva Systems Biology
• 31.13. Biotang Inc.
• 31.14. Reprokine
• 31.15. Molecular Depot

32. Global Tissue Plasminogen Activator Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tissue Plasminogen Activator Market

34. Recent Developments In The Tissue Plasminogen Activator Market

35. Tissue Plasminogen Activator Market High Potential Countries, Segments and Strategies

• 35.1 Tissue Plasminogen Activator Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tissue Plasminogen Activator Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tissue Plasminogen Activator Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료